Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 2, 2009, Pages 573-576

  Breusegem, Christophe ^a   Vandewalle, Evelien ^a   Van Calster, Joachim ^a   Stalmans, Ingeborg ^a   Zeyen, Thierry ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; TRIAMCINOLONE; DIAGNOSTIC AGENT; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MALE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROVOCATION TEST; RETINA VEIN OCCLUSION; SENSITIVITY AND SPECIFICITY; TELANGIECTASIA; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; CONFIDENCE INTERVAL; DIABETIC RETINOPATHY; DRUG EFFECT; INJECTION; INTRAOCULAR HYPERTENSION; LABORATORY DIAGNOSIS; MIDDLE AGED; PROSPECTIVE STUDY; RETINA MACULA EDEMA; TOPICAL DRUG ADMINISTRATION; VISUAL SYSTEM EXAMINATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DEXAMETHASONE; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; FALSE POSITIVE REACTIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; SENSITIVITY AND SPECIFICITY; TELANGIECTASIS; TRIAMCINOLONE ACETONIDE;

EID: 59449084574     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2625     Document Type: Article

References (26)

1. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics, I: the effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-491.
2. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70:500-507.
3. Akingbehin AO. Corticosteroid-induced ocular hypertension, II: an acquired form. Br J Ophthalmol. 1982;66:541-545.
4. Podos SM, Krupin T, Asseff C, Becker B. Topically administered corticosteroid preparations: comparison of intraocular pressure effects. Arch Ophthalmol. 1971;86:251-254.
5. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163-167.
6. Becker B, Hahn KA. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol. 1964;57:543-551.
7. Armaly MF. Inheritance of dexamethasone hypertension and glaucoma. Arch Ophthalmol. 1967;77:747-751.
8. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24:587-611.
9. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2002;86:247-248.
10. Jonas JB, Spandau UH, Kamppeter BA, et al. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2006;113:800-804.
11. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112: 1916.e1-e7.
12. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003;87:462-468.
13. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845-3849.
14. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593-598.
15. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-743.
16. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging. 2003;34:386-390.
17. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone- induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005; 112:139-143.
18. Galor A, Margolis R, Brasil OM, et al. Adverse events after intra-vitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114:1912-1918.
19. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005;40:63-68.
20. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol. 2006;141:579-580.
21. Jonas JB, Spandau UH, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration. J Ocul Pharmacol Ther. 2006; 22:194-199.
22. Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for reporting of diagnostic accuracy: towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003; 326:41-44.
23. Harper R, Reeves B. Reporting of precision of estimates for diagnostic accuracy: a review. BMJ. 1999;318:1322-1323.
24. Altman DG, Bland JM. Statistics notes: diagnostic tests 2: predictive values. BMJ. 1994;309:102.
25. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139-149.
26. Tammewar AM, Cheng L, Kayikcioglu OR, et al. Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br J Ophthalmol. 2008;92:810-813.